Haleon plc (NYSE:HLN) Given Average Rating of "Hold" by Brokerages

Haleon plc (NYSE:HLN - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $10.95.

HLN has been the topic of several analyst reports. Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Sanford C. Bernstein cut shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd.

Haleon Trading Up 0.2 %

HLN traded up $0.03 on Monday, reaching $10.22. 7,922,972 shares of the company's stock were exchanged, compared to its average volume of 11,451,854. The company has a market cap of $46.13 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon has a twelve month low of $8.12 and a twelve month high of $10.80. The company's 50 day moving average is $10.13 and its 200-day moving average is $9.81.

Haleon (NYSE:HLN - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Equities analysts predict that Haleon will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. This represents a yield of 1.6%. This is an increase from Haleon's previous -- dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio (DPR) is 58.97%.

Institutional Trading of Haleon

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after acquiring an additional 6,175,835 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Haleon during the fourth quarter worth $45,110,000. Raymond James Financial Inc. bought a new position in shares of Haleon in the 4th quarter worth about $42,193,000. FMR LLC boosted its holdings in shares of Haleon by 3.7% in the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock valued at $1,038,217,000 after buying an additional 3,909,545 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Haleon during the 4th quarter valued at about $39,628,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.